KROS vs TDG · rev $32.0K vs P/E 41, rev $8.83B
Keros Therapeutics Inc (KROS) versus Transdigm Group Incorporated (TDG) — a side-by-side from cached financials, not a winner call.
Keros Therapeutics Inc (KROS) is a biotechnology company listed on US.
Transdigm Group Incorporated (TDG) is a aerospace & defense company listed on NYSE.
Latest reported KROS revenue for 2026-06-30 was $32.0K. Net income was -$52.4M. Revenue was up 0.0% from 2026-03-31 to 2026-06-30. KROS currently screens at market cap $208.8M.
Latest reported TDG revenue for 2025-09-30 was $8.83B. Net income was $2.07B. TDG currently screens at market cap $73.65B and trailing P/E 41.1.
KROS currently screens at market cap $208.8M. TDG currently screens at market cap $73.65B and trailing P/E 41.1.
Not investment advice. Open the KROS and TDG stock pages for the full models.
Not investment advice.